Karen Bruckmann

Senior Director, Clinical Operations

Karen focuses on management for rare disease and novel therapy studies at Aceragen. She has more than 25 years of experience working at international clinical research organizations (CROs). Over the last 15 years she has been focusing on early phase studies. Most recently, she has focused on Lysosomal Storage Diseases, including Farber disease, and oversaw the Natural History and First in Human Studies from conception to study closeout.

At previous CROs, Karen created an Early Phase Monitoring Department, was the main point of contact for regional quality escalations and developed key performance indicators for Early Phase Clinical Operations. Karen studied as a Pharmacy Technician in Germany and obtained a Master of Science in Clinical Research from the University of Wales in Cardiff, UK.